• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23156 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Multi-stage evaluation and revision of information materials on the mammography screening programme]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer]
2024     Canary Health Service [Effectiveness, safety and cost-effectiveness of automated systems for detecting adverse drug reactions]
2024     Canary Health Service [Effectiveness, safety, and cost-effectiveness of out-of-hospital cardiac rehabilitation for ischemic heart disease or heart failure]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: reducing the carbon footprint of anesthetic agents inhaled in the operating room during general anesthesia - strategies and challenges to consider]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024     NIHR Health Technology Assessment programme Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews
2024     NIHR Health Technology Assessment programme Stopping anticoagulation for isolated or incidental pulmonary embolism: the STOPAPE RCT protocol
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Can the postoperative routine of intravenous/oral antibiotics after acute appendectomy in children with perforated appendicitis be shortened?
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Automated feedback based on digitalized follow-up of patients with unipolar depression receiving pharmacotherapy
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: judicious blood culture use]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment discussions: Does shared decision-making between doctor and patient regarding the choice of treatment lead to better results?]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isoflavone: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gabapentin: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clonidine: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     NIHR Health Services and Delivery Research programme Service innovations for people with multiple long-term conditions: reflections of a rapid evaluation team
2024     NIHR Health Technology Assessment programme Comparison of surgical or non-surgical management for non-acute anterior cruciate ligament injury: the ACL SNNAP RCT
2024     NIHR Health Services and Delivery Research programme Improving support and planning ahead for older people with learning disabilities and family carers: a mixed-methods study
2024     NIHR Health Technology Assessment programme Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     NIHR Health Technology Assessment programme Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation
2024     Scottish Health Technologies Group (SHTG) FDG PET dementia imaging - SHTG Recommendation
2024     Scottish Health Technologies Group (SHTG) Artificial intelligence supported clinician review of chest x-rays from patients with suspected lung cancer - SHTG Assessment
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide antibiotic use and prevent hearing loss in babies - SHTG Assessment
2024     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) - SHTG Assessment
2024     Penn Medicine Center for Evidence-based Practice (CEP) Interventions to prevent aspiration pneumonia in non-ventilated hospitalized patients
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of tezepelumab (Tezspire)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to the management of people with cholangiocarcinoma]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Acute myeloid leukemia treatment algorithm]
2024     Health Information and Quality Authority (HIQA) Magnetic resonance imaging-guided radiotherapy: Protocol for an evidence review to inform generic justification
2024     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of screening for abdominal aortic aneurysm in men
2024     Health Information and Quality Authority (HIQA) Evidence review of universal ultrasound screening for developmental dysplasia of the hip (DDH) in infants in Ireland
2024     Health Information and Quality Authority (HIQA) ¹⁷⁷Lutetium PSMA radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer: Evidence synthesis to support a generic justification decision
2024     Penn Medicine Center for Evidence-based Practice (CEP) Nurse-led delirium management and prevention
2024     HTA South [Artificial intelligence in breast cancer screening with mammography]
2024     National Institute for Health and Care Excellence (NICE) Intravascular lithotripsy for calcified arteries in peripheral arterial disease. NICE interventional procedures guidance 780
2024     National Institute for Health and Care Excellence (NICE) Temperature control to improve neurological outcomes after cardiac arrest. NICE interventional procedures guidance 782
2024     National Institute for Health and Care Excellence (NICE) Pharyngeal electrical stimulation for neurogenic dysphagia. NICE interventional procedures guidance 781
2024     National Institute for Health and Care Excellence (NICE) Endoscopic sleeve gastroplasty for obesity. NICE interventional procedures guidance 783
2024     National Institute for Health and Care Excellence (NICE) Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. NICE interventional procedures guidance 784
2024     National Institute for Health and Care Excellence (NICE) Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema. NICE interventional procedures guidance 785
2024     National Institute for Health and Care Excellence (NICE) Image-guided percutaneous laser ablation for primary and secondary liver tumours. NICE interventional procedures guidance 788
2024     National Institute for Health and Care Excellence (NICE) Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes. NICE interventional procedures guidance 787
2024     National Institute for Health and Care Excellence (NICE) Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver. NICE interventional procedures guidance 786
2024     Gesundheit Osterreich GmbH (GOeG) [Fecal immunochemical tests in comparison: umbrella review]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of thrombectomy for the treatment of ischemic stroke in Québec – Portrait from 2017-2018 to 2019-2020]
2024     The Danish Health Technology Council (DHTC) [Guided, internet-based cognitive behavioral therapy for the treatment of adults with mild or moderate depression]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: KIT D816V mutation detection by NAAT]
2024     NIHR Health Technology Assessment programme Evidence of quality of life for hospitalised patients with COVID-19: a scoping review
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of regular searches in the ICTRP Search Portal]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Momelotinib (myelofibrosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rezafungin (invasive candidiasis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vamorolone (Duchenne muscular dystrophy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegzilarginase (hyperargininaemia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Addendum to Project A23-123]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) - Addendum to Project A23-122]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus) – Addendum to Project A23-112]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer) – Addendum to Project A23-104]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quizartinib (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Patiromer (hyperkalaemia in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Use of structured support programmes in the monitoring of heart failure patients - an evidence map]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific analysis of clinical studies in the therapeutic area of wound treatment]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [General screening: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early screening in pregnant women with risk factors: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lifestyle interventions with the aim of lowering blood sugar levels: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metformin: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2024     NIHR Health Services and Delivery Research programme A service-user digital intervention to collect real-time safety information on acute, adult mental health wards: the WardSonar mixed-methods study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: continuous positive airway pressure devices for the treatment of obstructive sleep apnea]
2024     NIHR Health Services and Delivery Research programme Evaluating the real-world implementation of the Family Nurse Partnership in England: a data linkage study
2024     Health Sciences Institute in Aragon (IACS) Programme for the use of real world data in health technology assessment. Potential uses for real world data in the Spanish HTA Network
2024     NIHR Health Services and Delivery Research programme Factors influencing effective data sharing between health care and social care regarding the care of older people: a qualitative evidence synthesis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: breast cancer screening with breast tomosynthesis]
2024     NIHR Health Technology Assessment programme Doppler ultrasound surveillance of recently formed haemodialysis arteriovenous fistula: the SONAR observational cohort study
2024     NIHR Health Technology Assessment programme Clinical and cost‐effectiveness of pessary self‐management versus clinic-based care for pelvic organ prolapse in women: the TOPSY RCT with process evaluation
2024     NIHR Health Services and Delivery Research programme Service design for children and young people with common mental health problems: literature review, service mapping and collective case study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: linezolid plasma dosing]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: glossary of terms used in pharmacoeconomics]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of polypharmacy and use of potentially inappropriate medications among people aged 65 and over in Quebec]